Leading Expert On U.S. Health Reform Gives His Two Cents
Paul Keckley noted that things may get worse before they get better in the healthcare and lifescience industry in the United States.
Paul Keckley noted that things may get worse before they get better in the healthcare and lifescience industry in the United States.
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
GSV Capital Founder & CEO Michael Moe interviewed by OneMedRadio. GSV raised $50 million in an IPO in May 2011 to invest in emerging technology companies.
Copyright © 2024 | WordPress Theme by MH Themes